Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Factors associated with increased risk of VTE in patients with NSCLC

From: Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer

Patients Group SHR 95% CI P-value
Tumor histology (%)
 Non-adenocarcinoma 1   
 Adenocarcinoma 2.40 1.11–5.19 0.027
ECOG PS
 0–1 1   
 2–3 1.91 1.18–3.09 0.008
EGFR gene
 Mutated 1   
 Wild 1.81 1.07–3.07 0.028
Age
  ≥ 60 1   
  < 60 1.27 0.79–2.02 0.324
Sex
 Female 1   
 Male 1.03 0.63–1.66 0.920
Tumor Stage
 Distant metastasis 1   
 Localized 1.18 0.67–2.07 0.569
KRAS gene
 Wild 1   
 Mutated 1.10 0.52–2.32 0.814
  1. Abbreviations: CI confidence interval, ECOG Eastern Cooperative Oncology Group, SHR Sub-distribution hazard ratio, NSCLC non-small cell lung cancer, PS performance status, VTE venous thromboembolism
  2. *The variables were entered into the Fine-Gray regression model and included age, gender, ECOG PS (0–1 vs. 2–3), EGFR (mutated vs. wild), KRAS (mutated vs. wild), tumor histology (adenocarcinoma vs. nonadenocarcinoma), and tumor stage (localized stage vs. distant metastasis). All variables were shown in the table